News Briefing channel feed

Post-con­spir­a­cy claims, Arc­turus los­es an­oth­er ex­ec­u­tive amid board putsch; Gates Foun­da­tion hands $6.5M to No­var­tis for in­fec­tious di­ar­rhea treat­ment

8 years ago

Kad­mon shares jump on lim­it­ed IPF da­ta; Cel­lec­tis grant­ed two US patents for edit­ing T cells with CRISPR

8 years ago

BD ex­ec Goater re­places Bin­iszkiewicz as chief at Sur­face On­col­o­gy; Arde­lyx bids farewell to CSO Cald­well

8 years ago

Cel­gene prices $4.5B se­nior notes to help buy Juno; Health Af­fairs study says No­var­tis prices its CAR-T too high

8 years ago

Sage seeks $575M in pub­lic of­fer­ing; Pfiz­er inks dis­cov­ery pact with Chi­nese firm

8 years ago

Case West­ern/Sang­amo get $11M grant to wipe out HIV; Sage's de­pres­sion drug, GSK's vac­cine get break­through ther­a­py des­ig­na­tion

8 years ago

Nes­san Berming­ham re­turns to VC life; Sanofi's gener­ics unit gets two in­dus­try bid­ders in EMS and Tor­rent Phar­ma

8 years ago

Al­ler­gan taps Catal­en­t's Matthew Walsh as CFO; Re­Vi­ral meets end­points in PhI­Ia RSV tri­al

8 years ago

Voy­ager co-founder Steven Paul steps down from CEO seat; Al­ny­lam en­ters fi­nal stretch at the FDA with patisir­an

8 years ago

UCB, in­vestors back a neu­ro­sciences start­up called Syn­de­si; Ger­many's Biofron­tera in­creas­es US IPO pric­ing range

8 years ago

NIH, Fox Foun­da­tion al­lies with bio­phar­mas on $24M Parkin­son's project; FDA ac­cepts Ther­a­vance/My­lan NDA for COPD drug

8 years ago

Sunovion scores on PhI­II Parkin­son's study, shoot­ing for show­down with Acor­da; Puma out-li­cens­es ner­a­tinib to Is­raeli biotech

8 years ago

Roche touts CHMP nod for Hem­li­bra; Alder rais­es $200M for mi­graine drug launch

8 years ago

Vas Narasimhan joins the pow­er cir­cle at Davos; Ar­mo Bio, resTOR­bio rais­es $128M and $85M in IPO

8 years ago

Sum­mit shares shoot up on pos­i­tive DMD PhII; As­traZeneca and al­lies back a new in­cu­ba­tor/ac­cel­er­a­tor at Babra­ham

8 years ago

Ex-Al­ler­gan team at Bon­ti rais­es $15.5M for an­oth­er neu­ro­tox­in; Shire com­mits to pub­lish­ing in open ac­cess jour­nals on­ly

8 years ago

In­cyte tries to fend off TR­C's mi­ni-ten­der of­fer to in­vestors; Grit­stone On­col­o­gy scoops Acte­lion CFO Jean-Marc Bellemin

8 years ago

Fast-grow­ing Gilead buys an R&D cam­pus for $135M — re­port; Eu­re­ka bags $60M round for T cell R&D work

8 years ago

BeiGene ups of­fer­ing to a whop­ping $750M; Cel­gene back­ing $475M raise for Agios; Avastin copy­cat OK'd for Eu­rope

8 years ago

Car­mot clos­es $15M round to ad­vance di­a­betes drug; Ar­gos board clears re­verse stock split, moves to small cap mar­ket

8 years ago

France's Owkin rais­es $11M Se­ries A for AI-aid­ed drug de­vel­op­ment; As­traZeneca ex­pands dis­cov­ery deal with X-Chem

8 years ago

AveX­is wants $400M more for promis­ing SMA gene ther­a­py; Shang­Phar­ma part­ners with Ic­ahn School of Med­i­cine at Mount Sinai

8 years ago

HHS pick Azar draws the line on drug price ne­go­ti­a­tions at Medicare; As­traZeneca inks on­col­o­gy re­search deal at JPM

8 years ago

Brae­burn bags $110M in launch cash as PDU­FA date rolls up; En­do sub­poe­naed for doc­u­ments on opi­oid painkillers

8 years ago
First page Previous page 62636465666768 Next page Last page
A service from the Financial Times